Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A 1-YEAR MULTICENTER PLACEBO-CONTROLLED STUDY OF ACETYL-L-CARNITINE IN PATIENTS WITH ALZHEIMERS-DISEASE
Autore:
THAL LJ; CARTA A; CLARKE WR; FERRIS SH; FRIEDLAND RP; PETERSEN RC; PETTEGREW JW; PFEIFFER E; RASKIND MA; SANO M; TUSZYNSKI MH; WOOLSON RF;
Indirizzi:
UNIV CALIF SAN DIEGO,SCH MED,DEPT NEUROSCI,9500 GILMAN DR LA JOLLA CA92093 VAMC SAN DIEGO CA 00000 SIGMA TAU PHARMACEUT,DEPT NEUROL RES ROME ITALY UNIV IOWA,DIV BIOSTAT IOWA CITY IA 00000 NYU,MED CTR,DEPT PSYCHIAT NEW YORK NY 00000 UNIV HOSP CLEVELAND,ALZHEIMER CTR CLEVELAND OH 00000 MAYO CLIN ROCHESTER MN 00000 UNIV PITTSBURGH,DEPT PSYCHIAT PITTSBURGH PA 00000 UNIV S FLORIDA,CTR HLTH SCI,SUNEOAST GERONTOL CTR TAMPA FL 00000 UNIV WASHINGTON,DEPT PSYCHIAT SEATTLE WA 00000 COLUMBIA UNIV,DEPT NEUROL NEW YORK NY 00000
Titolo Testata:
Neurology
fascicolo: 3, volume: 47, anno: 1996,
pagine: 705 - 711
SICI:
0028-3878(1996)47:3<705:A1MPSO>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
COGNITIVE IMPAIRMENT; L-ACETYLCARNITINE; SENILE DEMENTIA; SYNAPSE LOSS; DOUBLE-BLIND; ONSET; RATS; HETEROGENEITY; CHROMOSOME-14; PROGRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
51
Recensione:
Indirizzi per estratti:
Citazione:
L.J. Thal et al., "A 1-YEAR MULTICENTER PLACEBO-CONTROLLED STUDY OF ACETYL-L-CARNITINE IN PATIENTS WITH ALZHEIMERS-DISEASE", Neurology, 47(3), 1996, pp. 705-711

Abstract

A 1-year, double-blind, placebo-controlled, randomized, parallel-group study compared the efficacy and safety of acetyl-L-carnitine hydrochloride (ALCAR) with placebo in patients with probable Alzheimer's disease (AD). Subjects with mild to moderate probable AD, aged 50 or older, were treated with 3 g/day of ALCAR or placebo (1 g tid) for 12 months. Four hundred thirty-one patients entered the study, and 83% completed 1 year of treatment, The Alzheimer's Disease Assessment Scale cognitive component and the Clinical Dementia Rating Scale were the primaryoutcome measures. Overall, both ALCAR- and placebo-treated patients declined at the same rate on all primary and most secondary measures during the trial. In a subanalysis by age that compared early-onset patients (aged 65 years or younger at study entry) with late-onset patients (older than 66 at study entry), we found a trend for early-onset patients on ALCAR to decline more slowly than early-onset AD patients on placebo on both primary endpoints. In addition, early-onset patients tended to decline more rapidly than older patients in the placebo groups. Conversely, late-onset-AD patients on ALCAR tended to progress morerapidly than similarly treated early-onset patients. The drug was very well tolerated during the trial. The study suggests that a subgroup of AD patients aged 65 or younger may benefit from treatment with ALCAR whereas older individuals might do more poorly. However, these preliminary findings are based on post hoc analyses, A prospective trial ofALCAR in younger patients is underway to test the hypothesis that young, rapidly progressing subjects will benefit from ALCAR treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:07:26